Healthcare News

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis...

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential...

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases,...

Portage, Michigan, March 23, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2026 Annual Meeting of Shareholders is scheduled as follows: Wednesday, May 6, 2026 – 12:00 p.m. Eastern Time ...

Los Angeles, March 23, 2026 (GLOBE NEWSWIRE) -- As demand for telehealth erectile dysfunction treatment access continues to grow in 2026, updated disclosures for MEDVi Quad, a...

– El éxito de la reunión con la FDA permite avanzar hacia el ensayo clínico de fase 3 propuesto del VCN-01 en combinación con gemcitabina/nab-paclitaxel para el tratamiento de primera línea del ACDP...

Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en...

OSE Immunotherapeutics to Present at Upcoming Investor Conferences